Life Science Investing Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial
Life Science Investing Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025
Life Science Investing Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine
Life Science Investing Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease
Anavex Life Sciences Doses First Patient in Extension Study to US Phase 2 Clinical Trial of ANAVEX2-73
Anavex Life Sciences Doses First Patient in Phase 2 Clinical Trial of ANAVEX®2-73 for the Treatment of Rett Syndrome
Anavex Life Sciences Receives Approval to Initiate Phase 2 Clinical Trial of ANAVEX2-73 for the Treatment of Parkinson’s Disease Dementia
Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX 2-73 for the Treatment of Early Alzheimer’s Disease
